New hope for lung cancer: combining immunotherapy with targeted local therapy
NCT ID NCT06840782
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests whether adding local treatments like radiation or surgery to standard immunotherapy can help people with oligometastatic non-small cell lung cancer live longer. About 124 participants will be randomly assigned to receive either immunotherapy alone or immunotherapy plus local treatments for all cancer spots. The study aims to see if the combination improves overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiation therapy (SBRT), interventional radiology, or minimally invasive surgery
What this could lead to
If successful, this could show that adding targeted local treatments to standard immunotherapy helps people with limited metastatic lung cancer live longer.
What could go wrong
This is a mid-stage trial with 124 participants, so results may not apply to all patients. Adding local treatments may increase side effects without improving survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Sainte-Catherine
RECRUITINGAvignon, Provence-Alpes-Côte d'Azur Region, 84000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Gustave Roussy
RECRUITINGVillejuif, Île-de-France Region, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut de Radiothérapie du Sud de l'Oise
RECRUITINGCreil, Hauts-de-France, 60100, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact